5.1.3.1 Safety Follow-up ............................................................................. 5.1.3.2 Survival Follow-up.......................................................................... 5.1.3.3 Response Follow-up ........................................................................ 5.1.4 Treatment with Additional Cycles ............................................................ 5.1.5 Treatment Beyond Progression ................................................................ 5.1.6 Data Monitoring Committee and Other External Committees ................ 1 3 4 4 6 1019 38 38 39 40 40 40 40 41 42 43 44 44 44 45 45 4546 46 49 51 52 54 54 55 58 59 60 61 61 61 62 62 62 62Clinical Protocol BMS-986226CA021002 anti-ICOS Revised Protocol No.: 04Date: 31-May-2019 6 Approved 5.0 v Approved 1.0 v 5.2 Number of Participants ..................................................................................... 5.3 End of Study Definition ....................................................................................